Article

Figures for Interest Grows in Treatment of Mood Disorders by Classic Psychedelics

Author(s):

Nicole Ledwos, MSc,M. Ishrat Husain, MD (Res), MBBS, MRCPsych

This is the extra table for "Interest Grows in Treatment of Mood Disorders by Classic Psychedelics."

Table. Registered Clinical Trials on ClinicalTrials.gov

Table. Registered Clinical Trials on ClinicalTrials.gov

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!
Related Videos
ketamine
drugs
glutamate
40 years
Tasphong/AdobeStock
Andrii Yalaanskyi/AdobeStock
Jorm Sangsorn/AdobeStock
RolfImages/AdobeStock
CravenA/AdobeStock
Related Content
genetics
June 17th 2025

ADHD With Bipolar Disorder: Genetics, Diagnosis, and New Thinking on Treatment

David N. Osser, MD
Here's to a Psychedelic Revolution
April 9th 2022

Here's to a Psychedelic Revolution

Amir Inamdar MBBS, DNB (Psych), MFPM
clinical trial
April 21st 2025

MindMed Begins Phase 3 Emerge Study of MM120 in Patients With Major Depressive Disorder

Grace Koennecke
Blue Light, Depression, and Bipolar Disorder
August 4th 2021

Blue Light, Depression, and Bipolar Disorder

Chris Aiken, MD Kellie Newsome, PMH-NP
COVID
March 11th 2025

Psilocybin Benefits Clinicians Traumatized on Front Line of COVID-19 Pandemic

Kenneth J. Bender, PharmD, MA
Andril Ylanskyl/AdobeStock
February 26th 2025

Agree to Disagree: A Collaborative Perspective From a Treatment Team and Disagreeing Patient

Fayzan Rab Jed Peter Mangal, MD
© 2025 MJH Life Sciences

All rights reserved.